Integrative multi-omics analysis identifies SNRPE as a key driver gene in Uterine corpus endometrial carcinoma: promoting tumor progression, and mediating immune evasion - Scorecard - MDSpire
Advertisement
Integrative multi-omics analysis identifies SNRPE as a key driver gene in Uterine corpus endometrial carcinoma: promoting tumor progression, and mediating immune evasion
Clinical Scorecard: Comprehensive multi-omics investigation reveals SNRPE as a crucial gene influencing tumor advancement and immune evasion in Uterine Corpus Endometrial Carcinoma
At a Glance
Category
Detail
Condition
Uterine Corpus Endometrial Carcinoma (UCEC)
Key Mechanisms
Dysregulation of splicing, immune evasion, T cell infiltration
Target Population
Patients with Uterine Corpus Endometrial Carcinoma
Care Setting
Clinical and research settings
Key Highlights
SNRPE identified as a driven oncogene linked to poor survival outcomes in UCEC.
Knocking down SNRPE suppresses tumor progression and restores T cell-mediated cytotoxicity.
SNRPE induces immune evasion by reducing major histocompatibility complex class I expression.
Guideline-Based Recommendations
Diagnosis
Evaluate SNRPE expression levels in UCEC patients for prognostic assessment.
Management
Consider targeting SNRPE for therapeutic strategies to enhance immunotherapy efficacy.
Monitoring & Follow-up
Monitor T cell infiltration and immune markers in UCEC patients undergoing treatment.
Risks
Inherent resistance to immunotherapy due to limited T cell infiltration.
Patient & Prescribing Data
Patients diagnosed with UCEC exhibiting SNRPE dysregulation.
Targeting SNRPE may improve response to immunotherapy and overall survival.
Clinical Best Practices
Integrate multi-omics approaches for comprehensive understanding of UCEC.
Utilize RNA sequencing and quantitative PCR for assessing splicing alterations.
